Status
Completed
Phase
Phase 3
Enrollment
349
Locations
1
Results
Not posted
Publications
0
Study summary
This is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D subjects. Subjects will be randomly assigned to IBI362 6 mg and Semalgutide 1 mg groups for 32 weeks (active-controlled treatment period). In the extension period, participants originally on mazdutide were assigned to continue for an additional 24 weeks with mazdutide 9 mg or 6 mg based on whether they achieved the weight-loss target. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 32-week active-controlled treatment period, a 24 week extension period and a 4-week drug withdrawal safety follow-up period.
Interventions
DRUG
Once-weekly injections of gradually increased doses of IBI362, subcutaneously (SC)，starting dose is IBI362 2.0 mg, continuous After 4 weeks of administration, increase to IBI362 4.0 mg. After 4 weeks of continuous administration, continue to increase to IBI362.
DRUG
Once-weekly injections of gradually increased doses of Semaglutide, subcutaneously (SC)，starting dose is semaglutide 0.25mg, after 4 weeks of continuous administration, increase to semaglutide 0.5mg, after 4 weeks of continuous administration, continue Upgrade to semaglutide 1.0 mg for 24 weeks.
Timeline
First posted
Dec 28, 2023
Study start
Feb 29, 2024
Primary completion
Sep 17, 2025
Study completion
Feb 9, 2026
Results posted
Not reported
Registry updated
Jun 11, 2026
Outcomes
Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss
Time frame · Week 32
Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥15% weight loss
Time frame · Week 32
Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥5% weight loss
Time frame · Week 32
Proportion of subjects who achieve composite endpoint of HbA1c<6.5% and ≥5%, ≥10% or ≥15% weight loss
Time frame · Week 32
Change from Baseline in HbA1c
Time frame · Week 32
Change in fasting plasma glucose(FPG) from baseline
Time frame · Week 32
Change in 7-point self-monitored blood glucose(SMBG) from baseline
Time frame · Week 32
Proportion of subjects achieving HbA1c < 7.0%, ≤ 6.5%, and < 5.7%
Time frame · Week 32
Change in body weight from baseline
Time frame · Week 32
Percent change in body weight from baseline
Time frame · Week 32
Change in waist circumference from baseline
Time frame · Week 32
Eligibility
Inclusion Criteria: * Male or female, age 18 years or older at the time of signing informed consent * T2D was diagnosed according to WHO standards in 1999(≤5 years) * The blood glucose was not well controlled after diet and exercise with/without sable metformin(≥1500mg/day，no more than 2550mg/day) within 3 months before screening, and the local laboratory tested 7.5% ≤ HbA1c ≤9.5% during screening * Have a BMI ≥28 kg/m2 Exclusion Criteria: * Subjects who the investigator thinks may be allergic to the components in the study drug or similar drugs * A self-reported change in body weight above 5% within 3 months before screening * Oral hypoglycemic drugs other metformin have been used within 2 months before screening. * Previous diagnosis of type 1 diabetes (including adult latent autoimmune diabetes) * There are active or untreated malignant tumors within 5 years before screening, or patients are in remission of clinical malignant tumors (except patients with skin basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ or papillary thyroid carcinoma who have no recurrence after surgery) * Mental illness existed in the past or at the time of screening, and the researcher thinks it is not suitable to participate in this study * Pregnant or lactating women, or men or women who are fertile and unwilling to use contraception throughout the study period * The investigator believes that the subject has any other factors that may affect the efficacy or safety evaluation of this study and is not suitable to participate in this study
Study locations
China. Showing up to 24 locations stored in the fast local snapshot.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
West China Hospital · Metabolic Dysfunction-Associated Steatohepatitis · Hepatic Steatosis
Phase 2 / Phase 3
Not yet recruiting
60
2026-07
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
1,481
2026-07
Tianjin Medical University · Type 2 Diabetes Mellitus (T2DM) · Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
Not applicable
Not yet recruiting
72
2026-07
Eli Lilly · Alcohol Use Disorder
Phase 2
Completed
308
2026-07
China National Center for Cardiovascular Diseases · Obesity & Overweight · Coronary Heart Disease
Phase 4
Not yet recruiting
116
2026-06
Shandong Provincial Hospital · Prediabetes · Impaired Fasting Glucose
Phase 4
Not yet recruiting
150
2026-06
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
200
2026-06
Innovent Biologics (Suzhou) Co. Ltd. · Overweight · Obesity
Phase 3
Recruiting
336
2026-05
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.